176 related articles for article (PubMed ID: 37683509)
1. Associations of comorbid substance use disorders with clinical outcomes in schizophrenia using electronic health record data.
Patel R; Chan KMY; Palmer EOC; Valko M; Guruswamy G; Ker S; Batra G; Rentería ME; Kollins SH
Schizophr Res; 2023 Oct; 260():191-197. PubMed ID: 37683509
[TBL] [Abstract][Full Text] [Related]
2. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.
Beaulieu S; Saury S; Sareen J; Tremblay J; Schütz CG; McIntyre RS; Schaffer A;
Ann Clin Psychiatry; 2012 Feb; 24(1):38-55. PubMed ID: 22303521
[TBL] [Abstract][Full Text] [Related]
3. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.
Lefebvre P; Muser E; Joshi K; DerSarkissian M; Bhak RH; Duh MS; Shiner B; Young-Xu Y
Clin Ther; 2017 Jul; 39(7):1380-1395.e4. PubMed ID: 28641996
[TBL] [Abstract][Full Text] [Related]
4. Medical complications associated with substance use disorders in patients with type 2 diabetes and hypertension: electronic health record findings.
Winhusen T; Theobald J; Kaelber DC; Lewis D
Addiction; 2019 Aug; 114(8):1462-1470. PubMed ID: 30851217
[TBL] [Abstract][Full Text] [Related]
5. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
6. Schizophrenia and comorbid substance use disorder: effects of antipsychotics.
Green AI
J Clin Psychiatry; 2005; 66 Suppl 6():21-6. PubMed ID: 16107180
[TBL] [Abstract][Full Text] [Related]
7. Substance use disorders and COVID-19: An analysis of nation-wide Veterans Health Administration electronic health records.
Hasin DS; Fink DS; Olfson M; Saxon AJ; Malte C; Keyes KM; Gradus JL; Cerdá M; Maynard CC; Keyhani S; Martins SS; Livne O; Mannes ZL; Sherman SE; Wall MM
Drug Alcohol Depend; 2022 May; 234():109383. PubMed ID: 35279457
[TBL] [Abstract][Full Text] [Related]
8. Patterns of polysubstance use and clinical comorbidity among persons seeking substance use treatment: An observational study.
Ellis JD; Rabinowitz JA; Ware OD; Wells J; Dunn KE; Huhn AS
J Subst Use Addict Treat; 2023 Mar; 146():208932. PubMed ID: 36880895
[TBL] [Abstract][Full Text] [Related]
9. Hospitalization Associated With Comorbid Psychiatric and Substance Use Disorders Among Adults With COVID-19 Treated in US Emergency Departments From April 2020 to August 2021.
Schieber LZ; Dunphy C; Schieber RA; Lopes-Cardozo B; Moonesinghe R; Guy GP
JAMA Psychiatry; 2023 Apr; 80(4):331-341. PubMed ID: 36790774
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders.
San L; Arranz B; Martinez-Raga J
Eur Addict Res; 2007; 13(4):230-43. PubMed ID: 17851245
[TBL] [Abstract][Full Text] [Related]
11. Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes: A Retrospective Cohort Study.
Ramakrishnan D; Sureshanand S; Pittman B; Radhakrishnan R
J Clin Psychiatry; 2022 Aug; 83(5):. PubMed ID: 36044600
[No Abstract] [Full Text] [Related]
12. Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia.
Wei Y; Yan VKC; Kang W; Wong ICK; Castle DJ; Gao L; Chui CSL; Man KKC; Hayes JF; Chang WC; Chan EW
JAMA Netw Open; 2022 Jul; 5(7):e2224163. PubMed ID: 35900760
[TBL] [Abstract][Full Text] [Related]
13. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.
Green AI; Tohen MF; Hamer RM; Strakowski SM; Lieberman JA; Glick I; Clark WS;
Schizophr Res; 2004 Feb; 66(2-3):125-35. PubMed ID: 15061244
[TBL] [Abstract][Full Text] [Related]
14. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts.
Lähteenvuo M; Luykx JJ; Taipale H; Mittendorfer-Rutz E; Tanskanen A; Batalla A; Tiihonen J
Br J Psychiatry; 2022 Dec; 221(6):758-765. PubMed ID: 36004532
[TBL] [Abstract][Full Text] [Related]
15. Substance use disorders among primary care patients screening positive for unhealthy alcohol use.
Metz VE; Palzes VA; Kline-Simon AH; Chi FW; Campbell CI; Weisner CM; Sterling SA
Fam Pract; 2022 Mar; 39(2):226-233. PubMed ID: 34964877
[TBL] [Abstract][Full Text] [Related]
16. Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review.
Arranz B; Garriga M; García-Rizo C; San L
Eur Neuropsychopharmacol; 2018 Feb; 28(2):227-242. PubMed ID: 29273271
[TBL] [Abstract][Full Text] [Related]
17. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review.
Hennessy EA; Tanner-Smith EE; Finch AJ; Sathe N; Kugley S
Campbell Syst Rev; 2018; 14(1):1-86. PubMed ID: 37131375
[TBL] [Abstract][Full Text] [Related]
18. Comorbid Cannabis and Tobacco Use Disorders in Hospitalized Patients with Psychotic-Spectrum Disorders.
Reeves LE; Gaudiano BA; Metrik J; Guzman Holst C; Morena A; Sydnor VJ; Weinstock LM; Epstein-Lubow G
J Dual Diagn; 2018; 14(3):171-180. PubMed ID: 30265850
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients.
John WS; Zhu H; Mannelli P; Schwartz RP; Subramaniam GA; Wu LT
Drug Alcohol Depend; 2018 Jun; 187():79-87. PubMed ID: 29635217
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical correlates of substance use disorders in South African Xhosa patients with schizophrenia.
Temmingh H; Susser E; Mall S; Campbell M; Sibeko G; Stein DJ
Soc Psychiatry Psychiatr Epidemiol; 2021 Apr; 56(4):695-706. PubMed ID: 32797244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
